BCAX (Bicara Therapeutics) 5-Day RSI: 96.01 (As of Jun. 29, 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $28.37
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics 5-Day RSI?

Bicara Therapeutics BCAX +5.58% 12 5-Day RSI is 96.01 as of Jun. 29, 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,421 Biotechnology companies, Bicara Therapeutics ranks worse than 99.23% on this metric.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-06-29), Bicara Therapeutics's 5-Day RSI is 96.01.

The industry rank for Bicara Therapeutics's 5-Day RSI or its related term are showing as below:

BCAX's 5-Day RSI is ranked worse than
99.23% of 1421 companies
in the Biotechnology industry
Industry Median: 46.23 vs BCAX: 96.01

Bicara Therapeutics  (NAS:BCAX) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Bicara Therapeutics 5-Day RSI Related Terms


BCAX vs ZYME, SRPT, INVA: 5-Day RSI Comparison

For the Biotechnology subindustry, Bicara Therapeutics's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bicara Therapeutics 5-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's 5-Day RSI falls into.


BCAX
12GF Score
Bicara Therapeutics Inc BCAX
5-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics  (NAS:BCAX) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 5-Day RSI →
What does a 5-Day RSI of 96.01 mean?
Bicara Therapeutics (BCAX) has a 5-Day RSI of 96.01 as of Jun. 29, 2026. According to the industry distribution chart, Bicara Therapeutics ranks #1410 out of 1421 companies in the Biotechnology industry, placing it in the top 99.2%.
Is Bicara Therapeutics' 5-Day RSI too high?
Bicara Therapeutics' current 5-Day RSI is 96.01. The Biotechnology industry median 5-Day RSI is 46.23. Bicara Therapeutics' value of 96.01 is 107.7% above this industry median. Based on the distribution chart, Bicara Therapeutics ranks #1410 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' 5-Day RSI compare to ZYME and SRPT?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #1410 out of 1421 companies for 5-Day RSI. This places Bicara Therapeutics in the lower half of its industry. The industry median 5-Day RSI is 46.23. Bicara Therapeutics' value of 96.01 is 107.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Biotechnology company?
The median 5-Day RSI among Biotechnology companies is 46.23, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bicara Therapeutics's current 5-Day RSI of 96.01 is 107.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 5-Day RSI is 46.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicara Therapeutics's current 5-Day RSI is 96.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current 5-Day RSI of 96.01. The current 5-Day RSI is 96.01 and 107.7% above the Biotechnology industry median of 46.23. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current 5-Day RSI is 96.01 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.37
Price